Update README.md

README.md

@@ -1,8 +1,15 @@
-# COMPOUND-Model
-**_tbd._**
+# Valproic acid-Model
+Whole-body PBPK model of valproic acid including non-linear binding with albumin in adults, children and children with hypoalbuminemia.
+This repository contains:
+- a PK-Sim snapshot (*.json ) file of the current PBPK model
+- static content (*.md files) as inputs for an evaluation plan
+- an evaluation plan (evaluation-plan.json) to create an evaluation report using the snapshot and static text blocks to display the performance of the model 
+This PBPK model is intended to be used as a basis for the implementation of non-linear protein binding using PBPK/Mobi.  The PBPK model helped assess the nonlinear dose-exposure relationship of VPA and the impact of albumin concentrations on the achievement of target exposure.
+This whole-body PBPK model of valproic acid has been developed using in published information and the parameters were optimized based on pharmacokinetic clinical data. 
 
-## Repository files
-**_tbd._**
+The model has then been evaluated simulating a large number of clinical studies and comparing with respective observed data, obtained from published clinical pharmacokinetic studies. 
+
+This model has been published[<sup>1</sup>](#references).
 
 ## Code of conduct
 Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology [code of conduct](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODE_OF_CONDUCT.md#contributor-covenant-code-of-conduct).
@@ -14,4 +21,4 @@ We encourage contribution to the Open Systems Pharmacology community. Before get
 The model code is distributed under the [GPLv2 License](https://github.com/Open-Systems-Pharmacology/Suite/blob/develop/LICENSE).
 
 ## References
-[1] **_tbd._**
+[1]  Karatza, E., Sinha, J., Maglalang, P. D., Edginton, A., & Gonzalez, D. (2024). Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia. Clinical pharmacokinetics, 63(10), 1435–1448. [https://doi.org/10.1007/s40262-024-01418-8](https://doi.org/10.1007/s40262-024-01418-8)